| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
AHR agonist 10 (Compound B19) (10 μM, 20 μM, 24 h) effectively enhanced the expression levels of CYP1A1 and CYP1B1 in AHR knockdown HaCaT cells [1]. AHR agonist 10 (5 μM) could inhibit the expression of CYP1A1, CYP1B1, CCL5, CCL20, IL-6, IL-8, S100A9, TLR4, TNF-α and TNFR1 at the mRNA level in Lipopolysaccharides (LPS)-induced HaCaT cells [1].
|
|---|---|
| ln Vivo |
AHR agonist 10 (1%, applied topically once daily for 7 days) inhibited the occurrence and progression of imiquimod-induced mirror-transcriptional silver fragmentation symptoms, resulting in a reduction of erythema and scales [1].
|
| Cell Assay |
RT-PCR[1]
Cell Types: AHR knockdown HaCaT cell Tested Concentrations: 10 μM , 20 μM Incubation Duration: 24 h Experimental Results: Enhanced the expression levels of CYP1A1 and CYP1B1 on the HaCaT cells. |
| Animal Protocol |
Animal/Disease Models: Male Babl/C mice (7-8 weeks old) were administered topically with Imiquimod (62.5 mg/mouse) on the hair-free back[1].
Doses: 1% Route of Administration: Topical application, once daily, 7 days Experimental Results: Exhibited the ability to decrease the thickness of the stratum corneum and stratum spinosum of the skin , ameliorating epidermal hyperplasia. Downregulated the expression of Ki67 and PCNA. Mitigated psoriasis-associated epidermal hyperplasia by curbing excessive epidermal cell proliferation. Enhanced the expression levels of ZO-1 and occludin. Downregulated the expression levels of IL-17, IL-23, and IL-17F, effectively halting the progression of psoriasis by disrupting the responsible cytokine cascade and subsequent inflammatory response. Effectively activated the AHR pathway, leading to enhanced expression levels of CYP1A1, CYP1B1, and HSP90. |
| References |
| Molecular Formula |
C18H20O3
|
|---|---|
| Molecular Weight |
284.35
|
| CAS # |
1191937-43-5
|
| Appearance |
Typically exists as solids at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5168 mL | 17.5840 mL | 35.1679 mL | |
| 5 mM | 0.7034 mL | 3.5168 mL | 7.0336 mL | |
| 10 mM | 0.3517 mL | 1.7584 mL | 3.5168 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
